enGene, Inc.
🇨🇦Canada
- Country
- 🇨🇦Canada
- Ownership
- Public, Subsidiary
- Established
- 1999-01-01
- Employees
- 51
- Market Cap
- -
- Website
- https://www.engene.com
Clinical Trials
1
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (100.0%)LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
Phase 1
Recruiting
- Conditions
- Superficial Bladder CancerNon-muscle Invasive Bladder Cancer With Carcinoma in Situ
- Interventions
- Drug: EG-70 (phase 1)Drug: EG-70 (phase 2)
- First Posted Date
- 2021-02-12
- Last Posted Date
- 2025-08-13
- Lead Sponsor
- enGene, Inc.
- Target Recruit Count
- 350
- Registration Number
- NCT04752722
- Locations
- 🇺🇸
The University of Alabama at Birmingham Clinical Research Unit (CRU), Birmingham, Alabama, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Urological Associates of South Arizona, Tucson, Arizona, United States
News
No news found